Journals / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 2

P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters

Pages
104–111
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a statistically significant difference between WDET (Grade I), WDEC (Grade II) and PDEC (Grade III) for p53 positivity (p<0.05) (Pearson chi-square test).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Gastrointestinal and pancreatic neuroendocrine tumors (GEPNETs) originate from the cells of the endocrine system.
📊
Key Findings & Data:The purpose of this study was to review the gastrointestinal and pancreatic neuroendocrine tumors and to evaluate p53, Ki-67 and CD 117 expressions with their clinicopathological correlations.
💡
Conclusion & Impact:There was a statistically significant difference between WDET (Grade I), WDEC (Grade II) and PDEC (Grade III) for p53 positivity (p<0.05) (Pearson chi-square test).
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Gastrointestinal and pancreatic neuroendocrine tumors (GEPNETs) originate from the cells of the endocrine system. Their molecular genetic mechanism of development and progression is complex and remains largely unknown. The purpose of this study was to review the gastrointestinal and pancreatic neuroendocrine tumors and to evaluate p53, Ki-67 and CD 117 expressions with their clinicopathological correlations. Materials and Methods: Twenty-one patients were reviewed and classified as having well-differentiated neuroendocrine neoplasm (WDET, Grade I), well-differentiated neuroendocrine carcinoma (WDEC, Grade II) and poorly differentiated neuroendocrine carcinoma (PDEC, Grade III). We performed immunohistochemical tests to characterize the expession of the immunoreactivity for synaptophysin, chromogranin, p53, Ki67 and CD 117.Results: Median age of 21 patients was 43 years. Thirteen (61.9%) patients were male and eight (38.1%) patients were female. Tumors were located in the stomach (38.1%), appendix (38.1%), duodenum (4.8%), ileum (4.8%), colon (9.5%), and pancreas (4.8%).Conclusion: There was a statistically significant difference between well-differentiated endocrine neoplasm (Grade I), and well-differentiated endocrine carcinoma (WDEC, Grade II) and PDEC for Ki-67 >20% (p<0.001) (Pearson chisquare test). There was a statistically significant difference between WDET (Grade I), WDEC (Grade II) and PDEC (Grade III) for p53 positivity (p<0.05) (Pearson chi-square test).

🔖

Cite This Article

ŞAHAN, E. K., ERDOĞAN, N., ULUSOY, İ., SAMET, E., AKYILDIZ, A. İ., GÖNÜLLÜ, D. (2015). P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 2, 104–111. https://ajindex.com/articles/409440

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 2009; 16: 72-8. [CrossRef] Rumilla KM, Erickson LA, Erickson AK, Lloyd RV. Galectin-4 expres- sion in carcinoid tumors.Endocrine Pathology 2006; 17: 243-50.
  2. Lubensky IA, Zhuang Z. Molecular genetic events in gastrointes- tinal and pancreatic neuroendocrine tumors. Endocrine Pathol 2007; 18: 156-62. [CrossRef] Demirkan B, Ünek İT, Eriksson B, et al. A patient with nonfunctional pancreatic neuroendocrine tumor andincidental metachronous colon carcinoma detected by positron emissiontomography: case report. Turk J Gastroenterol 2009; 20; 214-9. [CrossRef] Rothenstein J, Cleary SP, Pond GR, et al. Neuroendocrine tumors of the gastrointestinal tract; a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol 2008; 31: 64-70. [CrossRef] Oberg K. Neuroendocrine tumors of the gastrointestinal tract: re- cent advances in molecular genetics, diagnosis and treatment. Current Opinion in Oncology 2005; 17: 386-91. [CrossRef] Dayal Y. Neuroendocrine tumors of the gastrointestinal tract. Pa- thology Case Reviews 2006; 11: 268-81. [CrossRef] Lee H, Choi J, An JS, et al. The clinicopathological characteristics of gastrointestinal neuroendocrine tumors: an analysis of 65 cas- es. The Korean Journal of Pathology 2007; 41: 149-57. Kapran Y. [The Classification in Gastroenteropancreatic Tumors.] Dialogue in Endocrinology 2007; 4: 260-1.
  3. Li AF, Tsay SH, Liang WY, Li WY, Chen JY. Clinical significance of p16INK4a and p53 overexpression in endocrine tumors of the gas- trointestinal tract. Am J Clin Pathol 2006; 126: 856-65. [CrossRef] Couvelard A, Scoazec JY. A TNM classification for digestive endocrine tumors of midgut and hindgut: proposals from the European Neu- roendocrine Tumor Society (ENETS). Ann Pathol 2007; 27; 426-32. [CrossRef] Solcia E, Rindi G, Paolotti D, et al. Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors. Yale J Biol Med 1998; 71: 285-90.
  4. Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y. Diagnostic value of CD-X2 and TTF-1 expressions in seperating metastatic neuro- endocrine neoplasms of unknown origin. Appl Immunohisto- chem Mol Morphol 2007; 15: 407-14. [CrossRef] Doğusoy G, Göksel S, Durak H, et al. [Histopathological and im- münohistochemical examination in neuroendocrine tumors of the stomach.] Gastroenteroloji 1996; 7